human
coronavirus
hcov
common
caus
respiratori
ill
ri
despit
preexist
humor
immun
sera
obtain
near
onset
ri
week
later
part
prospect
studi
subject
evalu
ri
antibodi
common
hcov
strain
measur
enzymelink
immunosorb
assay
neutral
assay
compar
older
adult
cardiopulmonari
diseas
subject
younger
healthi
adult
subject
viru
shed
detect
respiratori
secret
polymeras
chain
reaction
hcovassoci
ill
occur
older
adult
age
year
younger
adult
age
year
bind
neutral
antibodi
higher
older
adult
ri
increas
bind
antibodi
also
increas
neutral
antibodi
hcov
increas
bind
antibodi
ri
frequent
increas
neutral
antibodi
viru
shed
frequent
younger
compar
older
adult
function
neutral
antibodi
stimul
often
bind
antibodi
explain
part
suscept
reinfect
hcov
monitor
bind
antibodi
may
sensit
serolog
detect
hcov
infect
antibodi
coronaviru
immun
neutral
respiratori
ill
viral
attach
infect
target
cell
concern
addit
neutral
antibodi
could
also
enhanc
infect
sarscov
littl
known
point
antigen
novel
hcov
strain
covid
human
innat
adapt
immun
respons
infect
provid
protect
reinfect
whether
cytokin
induct
may
enhanc
pathogen
sever
ill
antibodi
may
crossreact
among
viral
strain
least
within
hcov
genu
due
conserv
viral
antigen
epitop
may
includ
neutral
function
induc
repeat
infect
earlier
life
henc
serolog
reactiv
common
hcov
strain
may
differ
among
chronic
ill
older
adult
compar
younger
adult
previou
studi
older
adult
underli
chronic
pulmonari
diseas
report
serum
immunoglobulin
g
igg
antibodi
four
hcov
strain
preval
studi
subject
mucos
immunoglobulin
antibodi
four
common
hcov
strain
nasal
wash
specimen
detect
minor
patient
mucos
immun
respons
also
deserv
studi
respect
mitig
hcov
infect
although
strain
may
target
infect
lower
respiratori
tree
due
purport
receptor
usag
neutral
antibodi
direct
hcov
spike
protein
may
protect
nonfunct
bind
antibodi
direct
viral
protein
report
assess
whether
neutral
antibodi
hcov
strain
present
increas
acut
ri
chosen
studi
associ
increas
bind
antibodi
hcov
strain
detect
hcov
viral
nucleic
acid
respiratori
secret
assess
correl
serum
bind
neutral
antibodi
compar
antibodi
respons
older
chronic
ill
adult
healthi
young
adult
prospect
observ
studi
conduct
novemb
juli
assess
ri
patient
age
year
underli
chronic
lung
heart
diseas
group
total
n
subject
ri
assess
overal
healthi
young
adult
age
year
group
total
n
ri
assess
overal
enrol
subject
particip
year
receiv
phone
call
everi
week
remind
contact
studi
personnel
time
onset
acut
ri
evalu
studi
physician
nurs
clinic
either
three
symptom
acut
ri
fever
bodi
temperatur
accompani
two
symptom
acut
ri
describ
written
inform
consent
obtain
studi
subject
antigen
use
detect
bind
antibodi
enzymelink
immunosorb
assay
elisa
prepar
viru
grown
cell
respect
american
type
cultur
collect
atcc
manassa
va
atcc
gift
lia
van
der
hoek
univers
amsterdam
mock
antigen
prepar
uninfect
cell
virusinfect
cell
frozen
thaw
three
time
supernat
fluid
clarifi
cell
debri
centrifug
viru
concentr
overnight
centrifug
viru
pellet
resuspend
phosphatebuff
salin
concentr
viru
inactiv
psoralen
compound
sigma
st
loui
mo
follow
irradi
longwavelength
uv
light
describ
method
viral
inactiv
affect
viral
antigen
mock
antigen
prepar
way
uninfect
cell
grown
use
standard
tissu
cultur
techniqu
tag
recombin
nucleoprotein
n
mock
antigen
produc
plasmid
dna
vector
without
n
protein
gene
use
antigen
detect
antibodi
describ
viral
mock
antigen
stock
throughout
assay
use
coat
flatbottom
maxisorp
immunopl
nalgenunc
intern
rochest
ny
follow
sequenc
serum
serial
dilut
mous
antihuman
igg
conjug
horseradish
peroxidas
accur
chemic
scientif
westburi
ny
peroxidas
substrat
kpl
gaithersburg
md
optic
densiti
measur
nm
spectrophotomet
antihcov
serum
antibodi
titer
calcul
referencelin
leastsquaresfit
method
describ
posit
neg
control
sera
assay
confirm
consist
assay
also
sera
subject
evalu
assay
avoid
interassay
variabl
diego
ca
determin
serum
dilut
requir
protect
cell
cytotox
effect
hcov
viru
stock
use
throughout
assay
posit
neg
control
sera
assay
assur
reproduc
also
sera
subject
evalu
assay
avoid
interassay
variabl
descript
statist
fisher
exact
test
nonparametr
statist
test
use
compar
proport
continu
variabl
spearman
rankord
test
assess
correl
statist
analysi
done
use
statistica
releas
softwar
statsoft
inc
tulsa
ok
geometr
mean
bind
antibodi
titer
gmt
elisa
studi
enrol
sera
higher
entir
group
compar
ri
assess
group
ri
assess
group
subject
ill
associ
hcov
infect
serolog
chang
pcr
posit
hcov
common
respiratori
viru
associ
ri
parent
studi
enterorhinoviru
detect
polymeras
chain
reaction
describ
sera
bracket
hcovassoci
ri
focu
studi
follow
analys
like
provid
inform
util
measur
bind
neutral
antibodi
four
common
strain
hcov
ill
occur
older
adult
group
mean
age
year
min
max
year
younger
adult
group
mean
age
year
min
max
year
total
ri
threefold
increas
bind
antibodi
one
hcov
strain
compar
acut
convalesc
serum
antibodi
titer
includ
ri
threefold
increas
two
three
strain
one
ri
respiratori
secret
increas
bind
antibodi
ri
threefold
increas
bind
antibodi
titer
includ
nine
ill
three
group
six
group
three
five
group
group
neutral
antibodi
detect
two
acut
ri
sera
two
group
subject
detect
neutral
activ
ri
six
group
five
group
rise
neutral
antibodi
titer
six
two
group
four
group
four
one
group
three
group
four
ri
accompani
rise
neutral
antibodi
one
also
increas
therefor
total
number
ri
rise
neutral
antibodi
titer
one
hcov
strain
group
group
threefold
increas
elisa
antibodi
titer
predictor
minor
ill
increas
neutral
antibodi
hcov
tabl
eight
serum
pair
concomit
threefold
rise
elisa
antibodi
titer
two
hcov
strain
six
serum
pair
concomit
threefold
rise
elisa
antibodi
titer
three
hcov
strain
one
ill
includ
tabl
threefold
increas
elisa
antibodi
titer
detect
respiratori
secret
fourfold
rise
neutral
antibodi
consid
acut
convalesc
sera
ri
gmt
higher
group
group
subject
bind
antibodi
neutral
antibodi
figur
acut
ill
sera
gmt
bind
antibodi
higher
group
group
convalesc
sera
gmt
bind
antibodi
neutral
antibodi
higher
group
group
subject
figur
group
subject
acut
ill
bind
antibodi
titer
posit
correl
r
p
convalesc
serum
titer
correl
bind
neutral
antibodi
r
p
r
p
bind
antibodi
r
p
group
subject
acut
ill
serum
bind
antibodi
titer
correl
r
p
r
p
bind
neutral
antibodi
r
p
group
subject
combin
convalesc
serum
bind
neutral
antibodi
titer
correl
r
p
also
separ
r
p
bind
antibodi
correl
r
p
reinfect
coronavirus
reportedli
common
despit
presenc
humor
immun
respons
bind
antibodi
titer
threefold
associ
f
g
u
r
e
geometr
mean
titer
gmt
antibodi
two
method
human
coronavirus
hcov
shown
age
group
serum
pair
group
subject
year
age
serum
pair
group
subject
year
age
time
serum
collect
acut
collect
within
five
day
onset
acut
respiratori
ill
convalesc
collect
week
later
visit
refer
gmt
acut
convalesc
sera
togeth
patient
subject
group
tick
mark
end
vertic
line
show
correspond
percentil
antibodi
level
gmt
indic
measur
interpati
variabl
igg
bind
antibodi
gmt
measur
enzymelink
immunosorb
assay
elisa
shown
panel
neutral
antibodi
gmt
shown
panel
b
categor
reactiv
respect
hcov
strain
igg
immunoglobulin
g
acut
ri
inconsist
predictor
concomit
fourfold
neutral
antibodi
chang
chang
bind
antibodi
statist
better
antibodi
gmt
hcov
strain
increas
statist
compar
acut
convalesc
sera
calcul
valu
ill
gmt
calcul
evid
crossreact
antibodi
respons
least
relat
strain
alphacoronavirus
vs
betacoronavirus
choos
calcul
separ
gmt
subset
sera
threefold
chang
one
hcov
strain
would
assur
signific
rise
gmt
strain
threefold
bind
antibodi
chang
antigen
relat
infect
report
mediat
antibodi
protein
epitop
also
studi
protein
sequenc
neutral
antigen
suggest
serum
antibodi
neutral
clinic
hcov
isol
may
crossreact
well
laboratori
strain
hcov
use
neutral
assay
affect
sensit
neutral
assay
employ
inde
quasispeci
detect
respiratori
secret
patient
mutat
peak
region
spike
protein
could
lead
differ
antigen
lower
neutral
antibodi
level
respons
rate
laboratoryadapt
strain
older
group
subject
higher
level
bind
neutral
antibodi
acut
ri
younger
subject
group
probabl
due
previou
infect
cross
shed
contradistinct
hcovexperienc
subject
alreadi
seroposit
four
strain
onset
ri
increas
bind
antibodi
bracket
ri
signal
like
intercurr
hcov
infect
frequent
increas
neutral
antibodi
viral
nucleic
acid
detect
respiratori
secret
frequent
young
compar
older
adult
correl
bind
neutral
antibodi
homolog
relat
hcov
strain
though
statist
signific
comparison
unlik
simultan
infect
one
strain
hcov
concomit
increas
bind
neutral
antibodi
one
strain
consist
stimul
crossreact
antibodi
recal
immun
memori
suscept
repeat
infect
hcov
may
explain
part
stimul
neutral
antibodi
minor
ri
increas
bind
antibodi
sinc
bind
antibodi
increas
commonli
neutral
antibodi
may
sensit
seroepidemiolog
tool
neutral
antibodi
identifi
ri
due
common
hcov
strain
